Dr. Julian Bailes, a clinical professor of neurosurgery at the University of Chicago and co-director of the NorthShore Neurological Institute in Evanston, Illinois, stated he is days away from publishing a study of 20 subjects including former Dallas Cowboys star running back Tony Dorsett, one-time Buffalo Bills player Joe DeLamielleure, and former New York Giants lineman Leonard Marshall that establishes that CTE can be diagnosed successfully in living patients. The test uses a special PET scan to detect tau protein associated with CTE. Read the full article for additional details: http://bit.ly/1DUCett

Learning that a family member or loved one has dementia can be a difficult transition; the Alzheimer's Society offers tips and information about the disease and things to do together: http://bit.ly/1A9mnWD

The recently published data in BRAIN which showed the ability of Eltoprazine to counteract the distressing side effect of dyskinesia in Parkinson's Disease patients was featured in The Pharmaceutical Journal. Click here to read the full article: http://bit.ly/1LkboLO

Julianne Moore attended the 'Still Alice' premiere event and met with people living with dementia, discussing with them how their own experiences compared with events in the film. http://bit.ly/1z2o9UI

Amarantus announced today the execution of a biomarker services agreement with Anavex Life Sciences Corp. in which Amarantus will evaluate the pharmacodynamic effect of ANAVEX 2-73 and ANAVEX PLUS on the expression of the biomarker CD69 in specific sub-populations of peripheral blood lymphocytes using Amarantus’ proprietary Alzheimer’s blood diagnostic LymPro Test®. In parallel, the companies have entered into a Letter of Intent (“LOI”) for Amarantus to assist Anavex in planning the scope of the blood-based biomarker components of Anavex’ next larger, potentially Phase 3, Alzheimer’s disease clinical trial that is expected to follow the ongoing Phase 2a study currently enrolling subjects to collect additional safety and exploratory efficacy data in mild to moderate AD patients. Amarantus President & CEO Gerald Commissiong commented, “We are pleased to assist Anavex, our first customer, in evaluating the potential of ANAVEX 2-73 and ANAVEX PLUS to increase CD69 expression using LymPro in blood derived from AD patients.” Read the full press release for additional collaboration details: http://bit.ly/1yXp2Of

Viartis discussed the positive study results from Amarantus' Eltoprazine clinical trial published in BRAIN. Viartis highlighted that 5mg of Eltoprazine caused a significant reduction of L-dopa induced dyskinesias, as well as an antidyskinetic effect with 7.5 mg. Full study abstract and additional Parkinson's news available here: http://bit.ly/1yLLtG2

Visit our website to learn more about Eltoprazine for the treatment of levadopa-induced dyskinesia associated with Parkinson's disease. http://bit.ly/1z2pZ7Y

Amarantus announced today that its abstract titled, “The LymPro® Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively Intact Subjects,” was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2015) being held March 18-22, 2015, in Nice, France. The poster data to be presented at AD/PD 2015 by Louis Kirby, Corporate Advisor and Medical Director of Amarantus Diagnostics, confirms the consistent and accurate ability of the LymPro Test to distinguish univariate and multivariate combination indicators of lymphocyte proliferation AD biomarkers from controls. Read the full press release for additional presentation details: http://bit.ly/1LuLBRa

Parkinson's disease is both chronic, meaning it persists over a long period of time, and progressive, meaning its symptoms grow worse over time. Learn more from the National Institute of Neurological Disorders and Stroke: http://1.usa.gov/1A9me5M

DDNews spoke with Mr. Commissiong and Dr. Robert Stern about Amarantus' recent deals with DioGenix and Georgetown University. Mr. Commissiong stated that Amarantus anticipates that DioGenix's diagnostic test for multiple sclerosis (MSPrecise) has the potential to generate significant revenue as Amarantus continues to develop its diagnostic products focused on Alzheimers. Regarding the Georgetown University agreement, Dr. Robert Stern spoke about how it is critical for companies like Amarantus to develop effective diagnostic tests that can identify Alzheimer’s in its earliest stages in order to take full advantage of new treatments for the disease being developed. Read the full article available here: http://bit.ly/1A6UPkN

"All Things Considered," tells one man's Alzheimer's story from diagnosis, to sharing the news with his family, and now speaking publicly about the disease. Listen here: http://n.pr/1I2QTHo

Parkinson's symptoms may include but are not limited to: tremors, slowed movement (bradykinesia), rigid muscles, impaired posture and balance, loss of automatic movement, writing changes and speech changes. http://mayocl.in/1I2zkHr